Home > Boards > Free Zone > Penny Trading - Technical > GUMZSA/GREEN TEAM BOUNCE PLAYS

RASP .09 8-k new chairman

Public Reply | Private Reply | Keep | Last ReadPost New MsgNext 10 | Previous | Next
gumzsa Member Profile
Member Level 
Followed By 1,354
Posts 203,808
Boards Moderated 8
Alias Born 09/19/07
160x600 placeholder
Samsung Eyes Up to $17 Billion U.S. Chip-Plant Investment
South Korea's Samsung Electronics Co. is considering an investment of as much as $17 billion to build a chip-making factory in Arizona, Texas or New York, according to documents and people familiar with the company's plans.
Biden Administration to Review Possible Sanctions Relief in Response to Covid-19
Dow, S&P 500 Decline But Post Gains for the Week
Morgan Stanley CEO James Gorman Got a Big Raise for 2020
Investors Seek Out Riskiest Junk-Rated Bonds -- Update
Top Company News of the Day
Top Stories of the Day
Autodesk CEO Assumes Interim CFO Title
Labor Groups Push Biden Administration on Union-Friendly Priorities
U.S. Home Sales Reach Highest Level in 14 Years -- 2nd Update
Dow Drops But Notches Weekly Gain
Corn Falls as Funds Bail Out Ahead of Weekend
AstraZeneca Warns of Covid-19 Vaccine Shortfall in Europe -- Update
Comcast's NBCUniversal to Shut Down Sports Cable Channel NBCSN by Year-End -- 2nd Update
Comcast's NBCUniversal to Shut Down Sports Cable Channel NBCSN by Year-End -- Update
Keystone Pipeline Cancellation Raises Pressure on Canadian Producers -- Update
AstraZeneca Warns of Covid-19 Vaccine Shortfall in Europe
Stocks on Track for Weekly Gains
ECB Considers Ending Private Calls to Banks, Investors After Policy Meetings
Amazon Seeks to Postpone Alabama Unionization Vote -- Update
December Personal Income Expected to Rise -- Data Week Ahead
IBM Shares Are an Anomaly in a Hot Tech Sector
Investors Seek Out Riskiest Junk-Rated Bonds
AstraZeneca's Initial Vaccine Volumes in Europe to Be Lower Than Expected
Keystone Pipeline Cancellation Raises Pressure on Canadian Producers
gumzsa Member Level  Thursday, 10/15/20 11:38:16 AM
Re: None
Post # of 88129 
RASP .09 8-k new chairman


Willy Simon Appointed as Chairman of Rasna Therapeutics, Inc.

NEW YORK—Oct. 15, 2020 (BUSINESS WIRE)--Rasna Therapeutics, Inc. (OTCQB: RASP), a development biotechnology company focused on the development of disease-modifying drugs for hematological malignancies, today announced that Willy Simon has been appointed as the Chairman of Rasna Therapeutics, replacing Alessandro Padova, who resigned for personal reasons.

Mr. Simon is a banker and worked at Kredietbank N.V. and Citibank London before serving as an executive member of the Board of Generale Bank NL from 1997 to 1999 and as the chief executive of Fortis Investment Management from 1999 to 2002. He acted as chairman of Bank Oyens & van Eeghen from 2002 to 2004. He was previously chairman of AIM-traded Velox3 plc (formerly 24/7 Gaming Group Holdings plc) until 2014 and had been a director of Playlogic Entertainment Inc., a NASDAQ OTC listed company. Willy Simon has been the chairman of Bever Holdings, a company listed in Amsterdam, since 2006 and Chairman of Ducat Maritime since 2015. He also serves as the Executive Chairman of OKYO Pharma Ltd. and is a board member of Tiziana Life Sciences plc.

About Rasna Therapeutics, Inc.

Rasna Therapeutics, Inc. is a development stage biotechnology company focused primarily on the development of drug candidates for leukemia and lymphoma. Abnormal epigenetic modification is recognized to play an important role in the pathogenesis of acute myeloid leukemia (AML), leading to silencing of genes involved in tumor suppression and cellular reproduction. Rasna has a balanced portfolio targeting NPM1-mutated AML through direct and indirect disease-modifying approaches. The company is also exploiting inhibition of lysine specific demethylase-1 (LSD1), an enzyme involved in epigenetic control, as a promising and novel approach against AML. Rasna is entering preclinical development with a novel class of potent and selective reversible LSD1 regulators that have shown efficacy and LSD1 target modulation in in-vitro and in IND-enabling pre-clinical studies.

Forward-Looking Statements

This press release contains “forward-looking statements” as that term is defined in the Private Securities Litigation Reform Act of 1995, regarding the research, development and commercialization of pharmaceutical products. Such forward-looking statements are based on current expectations and involve inherent risks and uncertainties, including factors that could delay, divert or change any of them, and could cause actual outcomes and results to differ materially from current expectations. No forward-looking statement can be guaranteed. Forward-looking statements in the press release should be evaluated together with the many uncertainties that affect Rasna Therapeutics’ business and are made as of the date hereof and Rasna Therapeutics undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events, or otherwise. Investors should read the risk factors set forth in Rasna’s most recent periodic reports filed with the Securities and Exchange Commission, including Rasna’s Form 10-K for the year ended September 30, 2019.


Rasna Therapeutics Inc
Keeren Shah
E-mail: kshah@rasna.com

Public Reply | Private Reply | Keep | Last ReadPost New MsgNext 10 | Previous | Next
Follow Board Follow Board Keyboard Shortcuts Report TOS Violation
Current Price
Detailed Quote - Discussion Board
Intraday Chart
+/- to Watchlist
Consent Preferences